Chemomab director reports initial option holdings
Chemomab Therapeutics Ltd. director Darvish Nissim filed an initial ownership report showing existing equity interests in the company.
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. director Darvish Nissim filed an initial ownership report showing existing equity interests in the company. The filing lists several stock options over American Depositary Shares with different exercise prices and expiration dates, alongside a smaller direct holding of 300 American Depositary Shares.
Multiple option grants, including those from October 28, 2016, April 19, 2021, March 7, 2022, March 21, 2023, and June 1, 2024, are fully vested and exercisable. Another grant from June 14, 2023 vests in 36 monthly installments and is scheduled to be fully exercisable by June 14, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Darvish Nissim
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy American Depositary Shares) — 24,884 contracts (Direct);
American Depositary Shares — 300 shares (Direct)
Footnotes (6)
- F1. The options reported in this row were granted to the Reporting Person by the Issuer on October 28, 2016, and are fully vested and exercisable as of the date of this report.
- F2. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable in 36 equal monthly installments of 2.77%, such that all options reported in this row will be exercisable on June 14, 2026.
- F6. The options reported in this row were granted to the Reporting Person by the Issuer on June 1, 2024, and are fully vested and exercisable as of the date of this report.
Key Figures
Option underlying shares: 2,531 ADS
Option underlying shares: 2,971 ADS
Option underlying shares: 1,705 ADS
+5 more
8 metrics
Option underlying shares
2,531 ADS
Exercise price $3.20; expiration October 27, 2026
Option underlying shares
2,971 ADS
Exercise price $109.04; expiration April 19, 2031
Option underlying shares
1,705 ADS
Exercise price $14.12; expiration March 7, 2032
Option underlying shares
1,714 ADS
Exercise price $6.48; expiration March 21, 2033
Option underlying shares
5,143 ADS
Exercise price $6.80; expiration June 14, 2033
Option underlying shares
4,221 ADS
Exercise price $3.44; expiration June 1, 2034
Option underlying shares
6,599 ADS
Exercise price $5.24; expiration June 16, 2035
Direct ADS holding
300 ADS
Directly held American Depositary Shares
Key Terms
American Depositary Shares, Stock option (right to buy American Depositary Shares), fully vested and exercisable, vest and become exercisable in 36 equal monthly installments, +1 more
5 terms
fully vested and exercisable financial
"options reported in this row were granted ... and are fully vested and exercisable"
vest and become exercisable in 36 equal monthly installments financial
"options ... vest and become exercisable in 36 equal monthly installments of 2.77%"
initial ownership report financial
"Form 3 functions as an initial ownership report for the insider"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Chemomab (CMMB) Form 3 filing by Darvish Nissim show?
The Form 3 shows director Darvish Nissim’s initial ownership in Chemomab, mainly stock options on American Depositary Shares and 300 directly held ADS. It details each option grant’s exercise price, underlying share amount, vesting status, and expiration date.
What are the key exercise prices on Darvish Nissim’s Chemomab (CMMB) stock options?
The options have exercise prices of $3.20, $109.04, $14.12, $6.48, $6.80, $3.44 and $5.24 per American Depositary Share. Each price corresponds to a separate grant and is tied to specific vesting and expiration terms disclosed in the filing.
When do Darvish Nissim’s Chemomab (CMMB) options over ADS expire?
Expiration dates range from October 27, 2026 through June 16, 2035. Each option block has its own maturity, with earlier grants expiring sooner and later grants, such as those with a June 16, 2035 expiry, remaining outstanding for a longer period.
Which Chemomab (CMMB) options held by Darvish Nissim are already fully vested?
Options granted on October 28, 2016, April 19, 2021, March 7, 2022, March 21, 2023 and June 1, 2024 are described as fully vested and exercisable. A separate June 14, 2023 grant is vesting monthly and is expected to be fully exercisable by June 14, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
